November 14, 2019

November 13, 2019

Subscribe to Latest Legal News and Analysis

November 12, 2019

Subscribe to Latest Legal News and Analysis

November 11, 2019

Subscribe to Latest Legal News and Analysis

Life Sciences Congressional Investigations: Trends, Traps and Tips

On May 15, 2015, the Department of Justice (DOJ) announced that PharMercia Corporation, a comprehensive long-term provider of pharmacy services, operating across the country, agreed to pay the U.S. Government $31.5 million for allegedly violating the Controlled Substance Act (CSA) by knowingly dispensing Schedule II controlled drugs to residences of long-term care facilities without a valid prescription from a physician.  In addition, PharMercia also allegedly violated the False Claims Act (FCA) when it submitted claims to Medicare for these improperly dispensed drugs.

The Controlled Substance Act (CSA) is a federal law that regulates the prescribing and dispensing of psychoactive drugs, including narcotics, hallucinogens, depressants, and stimulants.  Schedule II controlled drugs are drugs or other substances that have a high potential for abuse.  According to the lawsuit filed on behalf of the government by Jennifer Denk, a pharmacist formerly employed by PharMerica and the whistleblower in this qui tam case, PharMercia allowed nursing home staff to administer Schedule II controlled substances, such as oxycodone and fentanyl, to its long-term residences — mostly elderly patients living in nursing homes — without obtaining a valid written prescription from their doctors.  In addition, the government alleged that PharMerica also allowed pharmacists to dispense the drugs without confirming that the prescriptions were legitimately approved by the patient’s doctor or medically necessary.  This type of practice is a violation of the CSA.

In the lawsuit, the government also accused PharMercia of billing Medicare for Schedule II medication administered during the long-term care of patients in nursing homes — medication that did not get the proper approval from the patient’s doctor.  Billing for improperly dispense drugs is a violation of the FCA and is considered Medicare fraud and $23.5 million of the settlement was allocated to settling the FCA claims.

A whistleblower who files a case against a company that has committed fraud against the government, may receive compensation of up to 30 percent of the amount ultimately recovered by the government.

© 2019 by Tycko & Zavareei LLP


About this Author

Jonathan K. Tycko leads the Whistleblower Practice Group of Tycko & Zavareei LLP

In recent years, the laws of the United States have undergone a whistleblower revolution. Federal and state governments now offer substantial monetary awards to individuals who come forward with information about fraud on government programs, tax fraud, securities fraud, and fraud involving the banking industry. Whistleblowers also now have important legal protections, designed to prevent retaliation and blacklisting.

The law firm of Tycko & Zavareei LLP works on the cutting edge of this whistleblower revolution, taking on even the most complex and confidential whistleblower...